HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Given the role of the EGFR/HER2 family of tyrosine kinases in breast cancer, we dissected the molecular basis of EGFR/HER2 kinase signaling in prostate cancer. Using the small molecule dual EGFR/HER2 inhibitor PKI-166, we show that the biologic effects of EGFR/HER-2 pathway inhibition are caused by reduced AR transcriptional activity. Additional genetic and pharmacologic experiments show that this modulation of AR function is mediated by the HER2/ERBB3 pathway, not by EGFR. This HER2/ERBB3 signal stabilizes AR protein levels and optimizes binding of AR to promoter/enhancer regions of androgen-regulated genes. Surprisingly, the downstream signaling pathway responsible for these effects appears to involve kinases other than Akt. These data suggest that the HER2/ERBB3 pathway is a critical target in hormone-refractory prostate cancer.

[1]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[2]  M. Gleave,et al.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. , 1992, Cancer research.

[3]  C. Turck,et al.  Growth Factors Signal to Steroid Receptors through Mitogen-activated Protein Kinase Regulation of p160 Coactivator Activity* , 2001, The Journal of Biological Chemistry.

[4]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[5]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[6]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[7]  G. Blackledge.  Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. , 2003, The Journal of urology.

[8]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[9]  A. Nordheim,et al.  MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. , 1996, Biochemical and biophysical research communications.

[10]  M. Iacocca,et al.  Human epidermal receptor-2 expression in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  C. Cordon-Cardo,et al.  Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[13]  S. Cheng,et al.  Phosphorylation enhances the target gene sequence-dependent dimerization of thyroid hormone receptor with retinoid X receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. F. Arnold,et al.  An antiestrogen: a phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. O’Malley,et al.  Hormone-dependent regulation of chicken progesterone receptor deoxyribonucleic acid binding and phosphorylation. , 1989, Endocrinology.

[16]  W. Isaacs,et al.  Androgen receptor outwits prostate cancer drugs , 2004, Nature Medicine.

[17]  A. Brinkmann,et al.  Androgen receptor phosphorylation. , 1996, Endocrine research.

[18]  B. O’Malley,et al.  Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.

[19]  E. Moss,et al.  Small-interfering RNAs in the radar of the interferon system , 2003, Nature Cell Biology.

[20]  A. Sugawara,et al.  Phosphorylation selectively increases triiodothyronine receptor homodimer binding to DNA. , 1994, The Journal of biological chemistry.

[21]  B. Keegan,et al.  Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. , 2000, Biochemical and biophysical research communications.

[22]  J. Shabanowitz,et al.  Androgen Receptor Phosphorylation , 2002, The Journal of Biological Chemistry.

[23]  J. Trapman,et al.  An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. , 1997, Molecular endocrinology.

[24]  M. Montminy,et al.  Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB , 1988, Nature.

[25]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[26]  J. Trapman,et al.  Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter (*) , 1996, The Journal of Biological Chemistry.

[27]  Chawnshang Chang,et al.  Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers* , 2003, Journal of Biological Chemistry.

[28]  Shaobo Zhang,et al.  An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene , 2000, Molecular and Cellular Endocrinology.

[29]  H. Herschman,et al.  Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Cordon-Cardo,et al.  HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  B. O’Malley,et al.  Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. S. French,et al.  Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer* , 2004, Journal of Biological Chemistry.

[34]  Pascal Furet,et al.  Tyrosine kinase inhibitors: From rational design to clinical trials , 2001, Medicinal research reviews.

[35]  S. Yeh,et al.  Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Umesono,et al.  Modulation of glucocorticoid receptor function by protein kinase A. , 1992, Molecular endocrinology.

[37]  M. Privalsky,et al.  Phosphorylation of Thyroid Hormone Receptors by Protein Kinase A Regulates DNA Recognition by Specific Inhibition of Receptor Monomer Binding* , 1998, The Journal of Biological Chemistry.

[38]  J. Lloreta,et al.  Her-2/neu Expression in Prostate Cancer , 2004, Clinical Cancer Research.

[39]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[40]  M. Privalsky,et al.  The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.

[41]  C. Cordon-Cardo,et al.  Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. , 1999, Cancer research.

[42]  Wei Xu,et al.  Androgen-induced recruitment of RNA polymerase II to a nuclear receptor–p160 coactivator complex , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[44]  Y. Whang,et al.  The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. , 2003, Journal of molecular endocrinology.

[45]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[46]  S. Groshen,et al.  Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. , 2001, The Journal of urology.

[47]  E. Wilson,et al.  Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. , 1992, The Journal of biological chemistry.

[48]  S. Hayward,et al.  The prostate: development and physiology. , 2000, Radiologic clinics of North America.

[49]  R. Deshaies,et al.  Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation , 2003, Nature Cell Biology.

[50]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Mendelsohn.  The epidermal growth factor receptor as a target for cancer therapy. , 2001, Endocrine-Related Cancer.

[52]  Anindya Dutta,et al.  Phosphorylation of serum response factor, a factor that binds to the serum response element of the c-FOS enhancer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[54]  M. Lazar,et al.  Modulating nuclear receptor function: may the phos be with you. , 1999, The Journal of clinical investigation.

[55]  Simak Ali,et al.  Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization , 1999, Molecular and Cellular Biology.

[56]  M. Lazar,et al.  Functional regulation of thyroid hormone receptor variant TR alpha 2 by phosphorylation , 1995, Molecular and cellular biology.

[57]  N. Blom,et al.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. , 1999, Journal of molecular biology.

[58]  C. Lange,et al.  Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[59]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[60]  J. Milbrandt,et al.  The phosphorylation and DNA binding of the DNA-binding domain of the orphan nuclear receptor NGFI-B. , 1993, The Journal of biological chemistry.

[61]  A. Bridges,et al.  A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.

[62]  C. Desjardins,et al.  Postnatal development of the testis, fighting behavior, and fertility in house mice. , 1973, Biology of reproduction.

[63]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[64]  M. Tsai,et al.  The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.

[65]  J. Trapman,et al.  Phosphorylation of androgen receptor isoforms. , 2004, The Biochemical journal.

[66]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[67]  Chawnshang Chang,et al.  Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase , 2002, The EMBO journal.

[68]  L. Cantley,et al.  Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3(*) , 1995, The Journal of Biological Chemistry.

[69]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[70]  Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. , 2002 .

[71]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[72]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[73]  Howard Hughes.  Lactacystin, Proteasome Function, and Cell Fate* , 1998, The Journal of Biological Chemistry.

[74]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[75]  I. Mellinghoff,et al.  Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. , 2002, Cancer research.